ABSTRACT
OBJECTIVE: There are currently no effective treatments for the prevention of dementia associated with vascular cognitive impairment. MicroRNAs regulate gene expression at the post-transcriptional level and play key roles in vascular disorders. TNFα (tumor necrosis factor-α) regulates blood-brain barrier breakdown through modification of cerebral tight junctions. Here, we sought key TNFα-responsive microRNAs that might influence blood-brain barrier breakdown via cerebral tight junction disruption in vascular cognitive impairment. APPROACH AND RESULTS: Using a mouse model of vascular cognitive impairment, chronic cerebral hypoperfusion within the white matter was induced with bilateral common carotid artery stenosis (BCAS) surgery. TNFα gene expression was increased in white matter post-BCAS surgery, and TNFα stimulation decreased claudin-5, ZO-1 (tight-junction protein 1), and occludin gene expression in murine brain endothelial cells. In silico analysis predicted 8 candidate microRNAs as regulators of claudin-5, ZO-1, and occludin gene expression. Of these, only miR-501-3p was upregulated by TNFα in vitro and was upregulated in the white matter after BCAS surgery. Further, miR-501-3p directly bound to the 3'-untranslated region of human ZO-1 and downregulated transendothelial electric resistance. In vivo administration of a locked nucleic acid -modified antisense oligonucleotide versus miR-501-3p suppressed BCAS-induced reduction of ZO-1 gene expression and blood-brain barrier disruption within the white matter and significantly ameliorated working memory deficits after BCAS surgery. CONCLUSIONS: We here provide the first evidence that the TNFα-miR-501-3p-ZO-1 axis plays an important role in the pathogenesis of cerebral hypoperfusion-induced working memory deficits and white matter lesions, as a result of blood-brain barrier breakdown via tight junction disruption. Therapeutic manipulation of miR-501-3p holds promise for limiting vascular cognitive impairment progression.
Subject(s)
Behavior, Animal , Blood-Brain Barrier/physiopathology , Capillary Permeability , Cerebrovascular Disorders/therapy , Cognition Disorders/therapy , Cognition , Genetic Therapy/methods , MicroRNAs/genetics , Oligonucleotides, Antisense/administration & dosage , 3' Untranslated Regions , Animals , Binding Sites , Blood-Brain Barrier/metabolism , Cerebrovascular Disorders/genetics , Cerebrovascular Disorders/physiopathology , Cerebrovascular Disorders/psychology , Claudin-5/genetics , Claudin-5/metabolism , Cognition Disorders/genetics , Cognition Disorders/physiopathology , Cognition Disorders/psychology , Disease Models, Animal , Electric Impedance , HEK293 Cells , Humans , Male , Mice, Inbred C57BL , MicroRNAs/metabolism , Occludin/genetics , Occludin/metabolism , Oligonucleotides, Antisense/genetics , Tight Junctions/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Zonula Occludens-1 Protein/genetics , Zonula Occludens-1 Protein/metabolismABSTRACT
Heteroatom-rich organoboron compounds have attracted attention as modulators of enzyme function. Driven by the unmet need to develop chemoselective access to boron chemotypes, we report herein the synthesis of α- and ß-aminocyano(MIDA)boronates from borylated carbonyl compounds. Activity-based protein profiling of the resulting ß-aminoboronic acids furnishes selective and cell-active inhibitors of the (ox)lipid-metabolizing enzyme α/ß-hydrolase domain 3 (ABHD3). The most potent compound displays nanomolar in vitro and in situ IC50 values and fully inhibits ABHD3 activity in human cells with no detectable cross-reactivity against other serine hydrolases. These findings demonstrate that synthetic methods that enhance the heteroatom diversity of boron-containing molecules within a limited set of scaffolds accelerate the discovery of chemical probes of human enzymes.
Subject(s)
Boron Compounds/chemistry , Enzyme Inhibitors/chemistry , Phospholipases/antagonists & inhibitors , Boron/chemistry , Boron/metabolism , Boron Compounds/chemical synthesis , Boron Compounds/metabolism , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/metabolism , Humans , Molecular Structure , Phospholipases/chemistry , Phospholipases/metabolism , Phospholipases A2ABSTRACT
Lipids play central roles in physiology and disease, where their structural, metabolic, and signaling functions often arise from interactions with proteins. Here, we describe a set of lipid-based chemical proteomic probes and their global interaction map in mammalian cells. These interactions involve hundreds of proteins from diverse functional classes and frequently occur at sites of drug action. We determine the target profiles for several drugs across the lipid-interaction proteome, revealing that its ligandable content extends far beyond traditionally defined categories of druggable proteins. In further support of this finding, we describe a selective ligand for the lipid-binding protein nucleobindin-1 (NUCB1) and show that this compound perturbs the hydrolytic and oxidative metabolism of endocannabinoids in cells. The described chemical proteomic platform thus provides an integrated path to both discover and pharmacologically characterize a wide range of proteins that participate in lipid pathways in cells.
Subject(s)
Lipid Metabolism , Proteins/analysis , Proteins/metabolism , Animals , Calcium-Binding Proteins/analysis , Cell Line, Tumor , DNA-Binding Proteins/analysis , Drug Evaluation, Preclinical , Eicosanoids/metabolism , Endocannabinoids/metabolism , HEK293 Cells , Humans , Lipid Metabolism/drug effects , Mice , Nerve Tissue Proteins/analysis , Nucleobindins , Proteome/analysis , Proteome/metabolism , Small Molecule Libraries/pharmacologyABSTRACT
OBJECTIVE: Genomewide association studies have implicated allelic variation at 9p21.3 in multiple forms of vascular disease, including atherosclerotic coronary heart disease and abdominal aortic aneurysm. As for other genes at 9p21.3, human expression quantitative trait locus studies have associated expression of the tumor suppressor gene CDKN2B with the risk haplotype, but its potential role in vascular pathobiology remains unclear. METHODS AND RESULTS: Here we used vascular injury models and found that Cdkn2b knockout mice displayed the expected increase in proliferation after injury, but developed reduced neointimal lesions and larger aortic aneurysms. In situ and in vitro studies suggested that these effects were attributable to increased smooth muscle cell apoptosis. Adoptive bone marrow transplant studies confirmed that the observed effects of Cdkn2b were mediated through intrinsic vascular cells and were not dependent on bone marrow-derived inflammatory cells. Mechanistic studies suggested that the observed increase in apoptosis was attributable to a reduction in MDM2 and an increase in p53 signaling, possibly due in part to compensation by other genes at the 9p21.3 locus. Dual inhibition of both Cdkn2b and p53 led to a reversal of the vascular phenotype in each model. CONCLUSIONS: These results suggest that reduced CDKN2B expression and increased smooth muscle cell apoptosis may be one mechanism underlying the 9p21.3 association with aneurysmal disease.